MedAlliance's SELUTION SLR Drug-Eluting Balloon (DEB) Receives FDA Investigational Device Exemption (IDE) Approval, Making it the First Limus DEB
PR96221
MedAlliance's SELUTION SLR Drug-Eluting Balloon (DEB) Receives FDA Investigational Device Exemption (IDE) Approval, Making it the First Limus DEB to be Available to US Patients
GENEVA, May 30, 2022 /PRNewswire=KYODO JBN/--
The SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon
that provides a controlled sustained drug release, similar to a drug-eluting
stent (DES). SELUTION SLR was also the first DEB (Drug Eluting Balloon) granted
"breakthrough device designation" by the FDA on March 4, 2019 and further in
September 25, 2019 for below-the-knee (BTK) indications in peripheral artery
disease.
This is a major milestone for MedAlliance. We have been able to successfully
complete the bench and pre-clinical testing required by the FDA and are ready
to begin enrolling US patients in a clinical study to support submission for
FDA PMA approval. We are delighted that US patients may also benefit from this
"Breakthrough technology", commented Jeffrey B. Jump MedAlliance Chairman and
CEO.
Photo - https://mma.prnewswire.com/media/1827076/MedAlliance_1.jpg
Logo - https://mma.prnewswire.com/media/1196864/MedAlliance_Logo.jpg
MedAlliance will begin enrollment in the Below-the-knee (BTK) IDE Randomized
Clinical Trial (RCT) SELUTION4BTK (ClinicalTrials.gov Identifier: NCT05055297)
immediately outside of US (OUS) and early this summer in US centers. Principal
investigators of the study are Doctors Ehrin Armstrong (US), Marianne Brodmann
(Austria), and Tjun Tang (Singapore).
SELUTION SLR was awarded CE Mark Approval for the treatment of peripheral
artery disease in February 2020. The device has shown early promising clinical
results in treatment of patients with Chronic Limb Threatening Ischemia (CLTI)
and below-the-knee artery disease. In the PRESTIGE study which was presented as
a late breaking trial at the VIVA 2021 congress by Dr Tjun Tang, use of
SELUTION SLR in complex BTK lesions resulted in sustained safety and efficacy
outcomes out to 18 months. An additional 75 patients with BTK disease and
SELUTION SLR treatment have been studied in the PRISTINE registry and the
results are scheduled to be presented at LINC 2022. Based on the early
promising data following the use of SELUTION SLR in treatment of BTK disease,
MedAlliance has moved forward with the design of the SELUTION4BTK RCT to
further investigate the safety and efficacy of this device and prepare for US
FDA approval.
SELUTION SLR's technology involves unique MicroReservoirs made from
biodegradable polymer intermixed with the anti-restenotic drug sirolimus. These
MicroReservoirs provide controlled and Sustained Limus Release (SLR) of the
drug. Extended release of sirolimus from stents has been demonstrated highly
efficacious in both coronary and peripheral vasculatures. MedAlliance's
proprietary CAT(TM)(Cell Adherent Technology) enables the MicroReservoirs to be
coated onto balloons and adhered to the vessel lumen when delivered via an
angioplasty balloon.
SELUTION SLR is available in Europe and all other countries where the CE Mark
is recognized.
Contact: Richard Kenyon, rkenyon@medalliance.com, +44-7831-569940
Source: MedAlliance
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。